UNSPSC 51401508: Lormetazepam

This classification denotes a benzodiazepine with the molecular formula C16H12Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GU56C842ZA, chemically known as 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one but generally known as lormetazepam, which bears US NIH Compound Identifier 13314. European Medicines Agency schedules Lormetazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08588MIG.

UNSPSC 51401508 Lormetazepam is a Commodity code that nominally names a specific benzodiazepine pharmaceutical product, but recent state and local solicitations tagged under this code do not align with procurement of lormetazepam itself. Instead, the code sees activity from county health departments, state pharmacy benefit agencies, and cooperative purchasing alliances seeking to procure a broader mix of pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems through competitive bidding and request-for-proposal processes. The mismatch between the code's narrow product name and the actual scope of work being purchased suggests this Commodity code may be misapplied in state and local procurement databases, or the code is used as a catch-all for various pharmaceutical and health-supply acquisitions that do not map cleanly to single-product taxonomy.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, response due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers and distributed across participating state and local government facilities in Minnesota and Oregon. Vendors responding to these solicitations must typically meet cGMP certification, Drug Supply Chain Security Act compliance, E-Verify requirements, and comprehensive insurance thresholds. Given the code's nominal focus on a single pharmaceutical and the recent activity showing broader pharmaceutical and health-supply procurement, buyers should verify that opportunities tagged under this code match their actual product or service scope before investing pursuit effort.